Ambroxol

Catalog No.S5710

For research use only.

Ambroxol, a substituted benzylamine, is an active metabolite of bromhexine. It is a potent inhibitor of the neuronal Na+ channels.

Ambroxol Chemical Structure

CAS No. 18683-91-5

Purity & Quality Control

Choose Selective Sodium Channel Inhibitors

Other Sodium Channel Products

Biological Activity

Description Ambroxol, a substituted benzylamine, is an active metabolite of bromhexine. It is a potent inhibitor of the neuronal Na+ channels.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 378.10
Formula

C13H18Br2N2O

CAS No. 18683-91-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04405596 Not yet recruiting Drug: Ambroxol Hydrochloride|Other: Placebo Lewy Body Disease Lawson Health Research Institute September 2020 Phase 1|Phase 2
NCT04388969 Recruiting -- Gaucher Disease|Parkinson Disease|GBA Gene Mutation Shaare Zedek Medical Center May 6 2020 --
NCT02941822 Completed Drug: Ambroxol Parkinson Disease University College London|The Cure Parkinson''s Trust December 2016 Phase 2
NCT02914366 Recruiting Drug: Ambroxol|Other: Placebo Parkinson''s Disease Dementia Lawson Health Research Institute|Weston Brain Institute|University of Western Ontario Canada|London Health Sciences Centre November 2015 Phase 2
NCT02373891 Completed Drug: Surfolase CR Healthy Volunteers Hyundai Pharmaceutical Co. LTD. April 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ambroxol | Ambroxol supplier | purchase Ambroxol | Ambroxol cost | Ambroxol manufacturer | order Ambroxol | Ambroxol distributor